The tax tribunal gave a detailed judgment when upholding HMCE in deciding that the sale of recombinant was liable to VAT. It recorded findings of fact that recombinant was "now considered as the treatment of choice by most clinicians and by the Haemophilia Society."
Chronology Information
Date:
Chapter/issue
Access to Treatment